Naibec Partners with University of Arkansas, a World-Leading Blood Cancer Research Institution

[Asia Economy Reporter Hyunseok Yoo] Naivek, a bio-specialized company in peptide fusion technology, announced on the 11th that it has signed a memorandum of understanding (MOU) with the University of Arkansas for Medical Sciences in the United States for joint research and development of blood cancer treatments based on peptide anticancer therapeutics.

This agreement focuses on conducting joint research and development on the "Effects of the bone anabolic agent on Multiple Myeloma Bone Disease." To this end, both parties signed the MOU and plan to engage in academic exchanges and mutual cooperation for research and development.

Multiple Myeloma is a blood cancer caused by abnormal differentiation and proliferation of plasma cells, a type of white blood cell responsible for the immune system in the bone marrow. It particularly invades bones, causing bone resorption that leads to fragility and fractures, and reduces bone marrow function due to marrow infiltration.

Although the exact pathogenesis of multiple myeloma has not yet been clarified, it is known to be associated with immune system abnormalities, genetic factors, and exposure to radiation and chemical substances.

The UAMS Myeloma Center at the University of Arkansas is one of the world's most prestigious research centers in the field of multiple myeloma and related diseases. It integrates innovative research and comprehensive patient care programs to develop and apply advanced treatments for multiple myeloma and related diseases.

Naivek has continuously conducted research on bone regeneration and targeted anticancer drugs based on peptides for several years. Through this joint research, it is expected to contribute not only to blood cancer but also to the development of treatments for bone diseases caused by bone marrow tumors.

A Naivek official stated, "Naivek's peptide-based anticancer therapeutics have demonstrated excellent anticancer effects, including research results showing a 98% inhibition rate of cancer metastasis through joint research and development with a French biotech company, as well as a reduction in tumor weight by more than 500%." He added, "The Myeloma Research Center at the University of Arkansas, which proposed this partnership, is a globally renowned research center in the field of blood cancer and places great trust in Naivek's peptide-based anticancer and bone regeneration research data." He further said, "Through this partnership, Naivek expects to achieve significant progress in the development of global blood cancer treatments."

Meanwhile, Naivek recently received approval from the Korean Ministry of Food and Drug Safety for a phase 1 clinical trial of the world's first osteoporosis treatment based on bone regeneration functional peptides and plans to conduct clinical trials through Seoul Asan Medical Center.

This content was produced with the assistance of AI translation services.